Documents

MatrixCare divestiture for $490M sharpens focus on core growth and funds shareholder returns.

Innovation and digital health drive growth in a vast, under-penetrated global sleep market.

Strong Q3 with double-digit revenue and EPS growth, margin expansion, and strategic acquisition.

Revenue up 11% to $1.42B, gross margin up 320 bps, EPS up 15% to $2.68.

AI-driven innovation, Big Tech partnerships, and U.S. expansion fuel growth and patient engagement.

Q1 delivered 9% revenue growth, margin expansion, and strong shareholder returns.

All proposals passed, with strong financial growth and strategic focus on AI and digital health.

ResMed targets double-digit growth by 2030 through innovation, data, and global expansion.

FY25 revenue hit $5.1B, with strong margins and innovation driving growth in large health markets.

Q4 FY25 delivered double-digit revenue growth, margin expansion, and increased capital returns.

Strong Q3 growth, margin expansion, and increased buybacks supported by robust demand and innovation.

Q2 revenue up 10%, EPS up 29%, with strong device and mask growth and margin expansion.